Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, side effects, and effectiveness of brenipatide LY3537031 in adults with Irritable Bowel Syndrome-Diarrhea IBS-D. This study compares brenipatide given under the skin to a placebo and aims to understand how well the drug is tolerated and how it impacts symptoms in participants aged 18 to 75. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Eli Lilly and Company. Participants receive either brenipatide or placebo, both administered subcutaneously. The study follows a parallel design where different groups receive either the experimental drug or the placebo. Treatment and evaluation last approximately 36 weeks, with key outcome measurements focused on symptom responses between weeks 9 to 16 and up to week 24. During the study, participants will record symptoms daily in an electronic diary, including abdominal pain and stool consistency. Researchers will monitor safety, side effects, and symptom changes through these reports and scheduled assessments. The main outcome is the percentage of days participants show significant symptom improvement during the critical weeks of treatment. The study includes a full follow-up period to assess lasting effects and safety throughout the 36 weeks.
Actively Recruiting
Researchers are studying tirzepatide to understand its effects on weight loss and the development of type 2 diabetes in adults who have obesity but do not have diabetes. This phase 4 study takes place in a real-world setting and aims to compare tirzepatide to standard care for these adults who also have at least one health condition related to their weight. The study is sponsored by Eli Lilly and Company and includes participants who are registered patients at participating sites. Participants will be randomly assigned to receive either tirzepatide injections once weekly along with standard care or standard care alone. The study will last about 260 weeks approximately 5 years, allowing researchers to observe long-term effects. The main focus is on how much participants body weight changes from the start of the study after 24 months, as well as whether they develop type 2 diabetes or other health complications related to obesity over 60 months. Throughout the study, participants will have various health measurements taken, including weight, waist size, blood pressure, cholesterol levels, liver enzymes, and quality of life assessments. Researchers will track the time it takes for participants to develop type 2 diabetes and monitor changes in blood sugar control and other health markers. Participants health resource use and overall wellbeing will also be evaluated. These assessments help understand the impact of tirzepatide compared to standard care over the long term.